A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Learn more about AIM ImmunoTech Inc’s (AIM) stock grades for Momentum, Estimate Revisions and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Jack Gilleland
| Share Statistics | AIM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5.6 | $252.6 | 4% |
|
| Shares Out (Mil) | 4.4 | 52.3 | 13% |
|
| Institutional Ownership | 52.5% | 92.1% | 36% |
|
| Float (Mil) | 19.3 | 40.2 | 28% |
|
| Beta | 1.17 | 0.95 | 69% |
|
| Avg Daily Volume (000s) | 769 | 455 | 66% |
|
| Price Change (52-week) |
(91.7%) | 52.9% | 4% |
|
| Growth | AIM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 0.6% | (9.9%) | 40% |
|
| EPS (5yr) | 28.2% | 16.0% | 79 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (63.1%) | (15.6%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.120) | ($0.630) | ($0.520) | |
| Month Ago EPS | ($0.120) | ($0.630) | ($0.520) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.370) | ($1.470) | ($1.470) | |
| Year/Year Chg | (82.7%) | (92.7%) | (91.5%) | |
| Financials | AIM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($13) | ($43) | 27% |
|
| EPS (TTM) | ($5.246) | ($1.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($11) | ($31) | 18% |
|
| Net Cash Flow (TTM) (Mil) | $5 | $5 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 13% |
|
| Enterprise Value (Q1) (Mil) | $7 | $180 | 6% |
|
| Valuation | AIM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.98 | 2.56 | 22% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | AIM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (29.8%) | 63.8% | 3% |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (179.0%) | (49.8%) | 2% |
|
| ROE | na | (55.5%) | na |
|
| Liabilities to Assets | 75.2% | 30.3% | 71% |
|
| F-Score | 2 | 3 | 7% |
|
AIM ImmunoTech Inc. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
